Clinical trial · Interventional
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates
NCT00765687CI-TRIAL-00012914BLESTcompletedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bisphosphates | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- Observation
- interventionNames
- Drug: bisphosphates
Primary outcomes (1)
- measure
- Skeleton-related event
- timeFrame
- 24 months
Secondary outcomes (1)
- measure
- overall survival
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \>18, either sex 2. Histologically confirmed non-small cell cancer 3. One bone metastasis at least confirmed by image(X ray,CT or others) 4. Without receiving zoledronic acid 5. Life expectancy \> 6 M 6. ECOG \<= 2 7. Signed ICF Exclusion Criteria: 1. Women who are pregnant or in lactation 2. Patients with hyperostosis 3. with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled 4. Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy 5. Severe co-morbidity of any type that may interfere with assessment of the patient for the study -
References
Publications (0)
Data not yet available
No reference posted for this study.